Literature DB >> 16476606

Management of in-sent restenosis after carotid artery stenting in high-risk patients.

Wei Zhou1, Peter H Lin, Ruth L Bush, Eric K Peden, Marlon A Guerrero, Panagiotis Kougias, Alan B Lumsden.   

Abstract

BACKGROUND: Carotid artery stenting (CAS) has emerged as an acceptable treatment alternative in patients with carotid bifurcation disease. Although early results of CAS have been promising, long-term clinical outcomes remain less certain. We report herein the frequency, management, and clinical outcome of in-stent restenosis (ISR) after CAS at a single academic institution.
METHODS: Clinical records of 208 CAS procedures in 188 patients with carotid stenosis of 80% or greater, including 48 (26.5%) asymptomatic patients, during a 42-month period were analyzed. Follow-up serial carotid duplex ultrasound scans were performed. Selective angiography and repeat intervention were performed when duplex ultrasound scans showed 80% or greater ISR. Treatment outcomes of ISR interventions were analyzed.
RESULTS: Over a median 17-month follow-up, 33 (15.9%) ISRs of 60% or greater were found, according to the Doppler criteria. Among them, seven patients (3.4%) with a mean age of 68 years (range, 65-87 years) developed high-grade ISR (> or =80%), and they all underwent further endovascular interventions. Six patients with high-grade ISR were asymptomatic, whereas one remaining patient presented with a transient ischemic attack. Five of seven ISRs occurred within 12 months of CAS, and two occurred at 18 months' follow-up. Treatment indications for initial CAS in these seven patients included recurrent stenosis after CEA (n = 4), radiation-induced stenosis (n = 1), and high-cardiac-risk criteria (n = 2). Treatment modalities for ISR included balloon angioplasty alone (n = 1), cutting balloon angioplasty alone (n = 4), cutting balloon angioplasty with stent placement (n = 1), and balloon angioplasty with stent placement (n = 1). Technical success was achieved in all patients, and no periprocedural complications occurred. Two patients with post-CEA restenosis developed restenosis after ISR interventions, both of whom were successfully treated with cutting balloon angioplasty at 6 and 8 months. The remaining five patients showed an absence of recurrent stenosis or symptoms during a mean follow-up of 12 months (range, 3-37 months). By using the Kaplan-Meier analysis, the freedom from 80% or greater ISR after CAS procedures at 12, 24, 36, and 42 months was 97%, 97%, 96%, and 94%, respectively.
CONCLUSIONS: Our study showed that ISR after CAS remains uncommon. Successful treatment of ISR can be achieved by endovascular interventions, which incurred no instance of periprocedural complications in our series. Patients who developed ISR after CEA were likely to develop restenosis after IRS intervention. Diligent ultrasound follow-up scans are important after CAS, particularly in patients with post-CEA restenosis.

Entities:  

Mesh:

Year:  2006        PMID: 16476606     DOI: 10.1016/j.jvs.2005.10.040

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  17 in total

Review 1.  Smooth muscle cell signal transduction: implications of vascular biology for vascular surgeons.

Authors:  Akihito Muto; Tamara N Fitzgerald; Jose M Pimiento; Stephen P Maloney; Desarom Teso; Jacek J Paszkowiak; Tormod S Westvik; Fabio A Kudo; Toshiya Nishibe; Alan Dardik
Journal:  J Vasc Surg       Date:  2007-06       Impact factor: 4.268

2.  Carotid artery stenting has increased risk of external carotid artery occlusion compared with carotid endarterectomy.

Authors:  Kevin Brown; Dina S Itum; Joshua Preiss; Yazan Duwayri; Ravi K Veeraswamy; Atef Salam; Thomas F Dodson; Luke P Brewster
Journal:  J Vasc Surg       Date:  2014-07-23       Impact factor: 4.268

3.  Fate of the external carotid artery following carotid interventions.

Authors:  Kevin Casey; Wei Zhou; Maureen M Tedesco; Weesam K Al-Khatib; Tina Hernandez-Boussard; Fritz Bech
Journal:  Int J Angiol       Date:  2009

4.  Carotid artery interventions for restenosis after prior stenting: is it different from interventions of de novo lesions? Results from the carotid artery stent (CAS)--registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte (ALKK).

Authors:  Ralf Zahn; Thomas Ischinger; Uwe Zeymer; Johannes Brachmann; Jens Jung; Hartwig Haase; Karl Eugen Hauptmann; Hubert Seggewiss; Ilse Janicke; Matthias Leschke; Harald Mudra
Journal:  Clin Res Cardiol       Date:  2010-07-02       Impact factor: 5.460

Review 5.  State of the art in carotid artery stenting: trial data, technical aspects, and limitations.

Authors:  Rajan A G Patel
Journal:  J Cardiovasc Transl Res       Date:  2014-04-26       Impact factor: 4.132

6.  Photodynamic therapy of balloon-injured rat carotid arteries using indocyanine green.

Authors:  Jih-Shyong Lin; Chia-Jung Wang; Wen-Tyng Li
Journal:  Lasers Med Sci       Date:  2018-03-28       Impact factor: 3.161

Review 7.  Management of De Novo Carotid Stenosis and Postintervention Restenosis-Carotid Endarterectomy Versus Carotid Artery Stenting-a Review of Literature.

Authors:  Runqi Wangqin; Paul R Krafft; Keaton Piper; Jay Kumar; Kaya Xu; Maxim Mokin; Zeguang Ren
Journal:  Transl Stroke Res       Date:  2019-02-22       Impact factor: 6.829

8.  Influence of the hostile neck on restenosis after carotid stenting.

Authors:  Kevin A Brown; Dina S Itum; Yazan Duwayri; James G Reeves; Ravi Rajani; Ravi K Veeraswamy; Shipra Arya; Atef Salam; Thomas F Dodson; Luke P Brewster
Journal:  Ann Vasc Surg       Date:  2014-06-12       Impact factor: 1.466

Review 9.  Comparative Review of the Treatment Methodologies of Carotid Stenosis.

Authors:  Coney Bae; Mauricio Szuchmacher; John B Chang
Journal:  Int J Angiol       Date:  2015-05-18

10.  Recurrent stenosis following carotid artery stenting treated with a drug-eluting balloon: a single-center retrospective analysis.

Authors:  C Pohlmann; J Höltje; M Zeile; F Bonk; P P Urban; R Brüning
Journal:  Neuroradiology       Date:  2017-10-20       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.